ERBB2 and breast cancer: For instance, human epidermal growth factor receptor 2 (HER2) positive breast cancers result in better clinical benefits from HER2-targeted mAbs (e.g., trastuzumab and pertuzumab) than mAbs that target HER2 negative breast cancer markers (e.g., everolimus)93.